Massachusetts Institute of Technology
Sign in

What Can We Learn From Related Industries?

08/12/2004 3:15PM Wong Auditorium
Scott Sarazen, Senior Vice President, Life Sciences, MassDevelopment; Andrew Parece, Vice President, Analysis Group/Economics Analysis Group, Inc; Tamsin S. Randlett, Senior Director, Government Affairs, Gap Inc. ; Stephen M. Sammut, Venture Partner, Burrill & Company

Description: In some ways, the pharmaceutical industry is unique from other industries, its upfront R&D costs, for instance are extremely high. But these panelists see some commonalities with other business sectors, and offer observations and counsel to drug manufacturers. Andrew Parece focuses on the trade of high tech goods, such as software, digital cameras and DVDs. There are difficulties controlling the free flow of these goods, and their prices, across borders a challenge the drug industry also confronts today. Parece suggests that pharma companies "leverage their competitive advantage 'to differentiate products, and turn offerings into products and services such as patient assistance and education, and disease management." Tamsin Randlett of Gap, Inc. deals more with issues on the manufacturing end. The Gap outsources clothing production to companies in parts of the world where wage and labor standards lag. To respond to concerns about equity and human rights, Randlett partners with international labor organizations and NGOs. She suggests pharmaceutical industries similarly "leverage world health organizations 'to bring greater credibility to your efforts" and sit down with politicians, even those opposed to industry positions. Stephen Sammut's venture capital group invests in the biosecurity business. Just as in drug manufacturing, biosecurity involves risky and expensive R&D, licensing and liability questions, and unpredictable market size. Since "northern hemisphere concerns about biosecurity are the daily disease burden of many countries in the southern hemisphere," says Sammut, one answer to the pricing problem may be creating drugs useful for both markets simultaneously.

Host(s): Sloan School of Management, MIT Sloan School of Management

Comments (0)

It looks like no one has posted a comment yet. You can be the first!

You need to log in, in order to post comments.

MIT World — special events and lectures

MIT World — special events and lectures

Category: Events | Updated 2 years ago

Created
December 13, 2011 11:18
Category
Tags
License
All Rights Reserved (What is this?)
Additional Files


Viewed
4613 times

More from MIT World — special events and lectures

Why Robbie Can't Learn: The Difficulty of Learning in Autonomous Agents

Why Robbie Can't Learn: The Difficu...

Added almost 6 years ago | 00:54:23 | 5412 views

Engineering for the Ecological Age: Lessons from History

Engineering for the Ecological Age:...

Added almost 6 years ago | 01:24:00 | 17483 views

enChanting Musical Artifacts in Unlikely Places: Rare Resources in MIT's Lewis Music Library

enChanting Musical Artifacts in Unl...

Added almost 6 years ago | 00:53:15 | 10893 views

MIT Perspective on Engineering Systems

MIT Perspective on Engineering Systems

Added almost 6 years ago | 01:13:00 | 7733 views

The OpenCourseWare Initiative: A New Model for Sharing

The OpenCourseWare Initiative: A Ne...

Added almost 6 years ago | 00:37:43 | 3324 views

Islam and the Challenge of Democracy

Islam and the Challenge of Democracy

Added almost 6 years ago | 01:21:00 | 4035 views